These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
304 related articles for article (PubMed ID: 36272139)
61. Regulation of temozolomide resistance in glioma cells via the RIP2/NF-κB/MGMT pathway. Hu YH; Jiao BH; Wang CY; Wu JL CNS Neurosci Ther; 2021 May; 27(5):552-563. PubMed ID: 33460245 [TBL] [Abstract][Full Text] [Related]
62. MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3β in glioblastoma. Tian T; Mingyi M; Qiu X; Qiu Y Oncotarget; 2016 Nov; 7(48):79584-79595. PubMed ID: 27792996 [TBL] [Abstract][Full Text] [Related]
63. Oxidative cytotoxic agent withaferin A resensitizes temozolomide-resistant glioblastomas via MGMT depletion and induces apoptosis through Akt/mTOR pathway inhibitory modulation. Grogan PT; Sarkaria JN; Timmermann BN; Cohen MS Invest New Drugs; 2014 Aug; 32(4):604-17. PubMed ID: 24718901 [TBL] [Abstract][Full Text] [Related]
64. Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. Kitange GJ; Carlson BL; Schroeder MA; Grogan PT; Lamont JD; Decker PA; Wu W; James CD; Sarkaria JN Neuro Oncol; 2009 Jun; 11(3):281-91. PubMed ID: 18952979 [TBL] [Abstract][Full Text] [Related]
65. The effects of tumor treating fields and temozolomide in MGMT expressing and non-expressing patient-derived glioblastoma cells. Clark PA; Gaal JT; Strebe JK; Pasch CA; Deming DA; Kuo JS; Robins HI J Clin Neurosci; 2017 Feb; 36():120-124. PubMed ID: 27865821 [TBL] [Abstract][Full Text] [Related]
66. Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide. van Nifterik KA; van den Berg J; van der Meide WF; Ameziane N; Wedekind LE; Steenbergen RD; Leenstra S; Lafleur MV; Slotman BJ; Stalpers LJ; Sminia P Br J Cancer; 2010 Jun; 103(1):29-35. PubMed ID: 20517307 [TBL] [Abstract][Full Text] [Related]
67. Sulforaphane reverses chemo-resistance to temozolomide in glioblastoma cells by NF-κB-dependent pathway downregulating MGMT expression. Lan F; Yang Y; Han J; Wu Q; Yu H; Yue X Int J Oncol; 2016 Feb; 48(2):559-68. PubMed ID: 26648123 [TBL] [Abstract][Full Text] [Related]
68. Specificity protein 1-modulated superoxide dismutase 2 enhances temozolomide resistance in glioblastoma, which is independent of O Chang KY; Hsu TI; Hsu CC; Tsai SY; Liu JJ; Chou SW; Liu MS; Liou JP; Ko CY; Chen KY; Hung JJ; Chang WC; Chuang CK; Kao TJ; Chuang JY Redox Biol; 2017 Oct; 13():655-664. PubMed ID: 28822335 [TBL] [Abstract][Full Text] [Related]
69. Mismatch repair proteins play a role in ATR activation upon temozolomide treatment in MGMT-methylated glioblastoma. Ganesa S; Sule A; Sundaram RK; Bindra RS Sci Rep; 2022 Apr; 12(1):5827. PubMed ID: 35388070 [TBL] [Abstract][Full Text] [Related]
70. A Promising Way to Overcome Temozolomide Resistance through Inhibition of Protein Neddylation in Glioblastoma Cell Lines. Brandt B; Németh M; Berta G; Szünstein M; Heffer M; Rauch TA; Pap M Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175636 [TBL] [Abstract][Full Text] [Related]
71. A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma. Chen X; Zhang M; Gan H; Wang H; Lee JH; Fang D; Kitange GJ; He L; Hu Z; Parney IF; Meyer FB; Giannini C; Sarkaria JN; Zhang Z Nat Commun; 2018 Jul; 9(1):2949. PubMed ID: 30054476 [TBL] [Abstract][Full Text] [Related]
72. Effects of Long-Term Temozolomide Treatment on Glioblastoma and Astrocytoma WHO Grade 4 Stem-like Cells. Feldheim J; Kessler AF; Feldheim JJ; Schulz E; Wend D; Lazaridis L; Kleinschnitz C; Glas M; Ernestus RI; Brandner S; Monoranu CM; Löhr M; Hagemann C Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563629 [TBL] [Abstract][Full Text] [Related]
73. Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells. Happold C; Roth P; Wick W; Schmidt N; Florea AM; Silginer M; Reifenberger G; Weller M J Neurochem; 2012 Jul; 122(2):444-55. PubMed ID: 22564186 [TBL] [Abstract][Full Text] [Related]
74. [Curcumol reverses temozolomide resistance in glioma cells by regulating the UTX/MGMT axis]. Sun J; Xing J; Tan R; Qian Y; Tian N Nan Fang Yi Ke Da Xue Xue Bao; 2023 Oct; 43(10):1697-1705. PubMed ID: 37933645 [TBL] [Abstract][Full Text] [Related]
75. Olea europaea Leaf Extract Improves the Efficacy of Temozolomide Therapy by Inducing MGMT Methylation and Reducing P53 Expression in Glioblastoma. Tezcan G; Tunca B; Demirci H; Bekar A; Taskapilioglu MO; Kocaeli H; Egeli U; Cecener G; Tolunay S; Vatan O Nutr Cancer; 2017; 69(6):873-880. PubMed ID: 28718668 [TBL] [Abstract][Full Text] [Related]
76. Dual MGMT inactivation by promoter hypermethylation and loss of the long arm of chromosome 10 in glioblastoma. Richard S; Tachon G; Milin S; Wager M; Karayan-Tapon L Cancer Med; 2020 Sep; 9(17):6344-6353. PubMed ID: 32666673 [TBL] [Abstract][Full Text] [Related]
77. Framework nucleic acid-based nanoparticles enhance temozolomide sensitivity in glioblastoma. Lan Y; Li X; Liu B; Lu J; Zuo B; Wang Y; Cao S; Fu X; Yue Q; Luo X; Zhong X; Dong Y; Wang Z; Yang T; Xie X; Zeng T; Zhang M; Wang Y; Shen Y; Zuo H; Zhao Y; Zhang C; Guo H Drug Resist Updat; 2024 Sep; 76():101122. PubMed ID: 39079407 [TBL] [Abstract][Full Text] [Related]
78. Up-regulation of miR-370-3p restores glioblastoma multiforme sensitivity to temozolomide by influencing MGMT expression. Gao YT; Chen XB; Liu HL Sci Rep; 2016 Sep; 6():32972. PubMed ID: 27595933 [TBL] [Abstract][Full Text] [Related]
79. CRISPR-Cas9 library screening combined with an exosome-targeted delivery system addresses tumorigenesis/TMZ resistance in the mesenchymal subtype of glioblastoma. Zhao J; Cui X; Zhan Q; Zhang K; Su D; Yang S; Hong B; Wang Q; Ju J; Cheng C; Li C; Wan C; Wang Y; Zhou J; Kang C Theranostics; 2024; 14(7):2835-2855. PubMed ID: 38773970 [No Abstract] [Full Text] [Related]